Our Strategy & Mission
Our strategy is to identify the molecular foundation of spinal disorders and to use these discoveries to develop DNA-based diagnostic products. We have always believed that prognostic testing is the cornerstone of better patient outcomes. Personalized information creates the opportunity for more informed decision-making by both physicians and patients long before these devastating spinal disorders progress.
We are excited by the progress we have made in developing a proprietary understanding of the genetic foundation of Scoliosis, but this is only the beginning of the change we intend to bring to spine care. We have already begun the development of new projects aimed at the most widespread spinal disorders.
We are currently launching product development programs for:
- DNA-based diagnostics/prognostics for other spinal disorders (Degenerative Disc Disease, Spondylolisthesis, Scheuermann's Disease, Osteoarthritis and Osteoporosis)
- Molecular therapeutics and/or pharmaceuticals targeting spinal disorders
The right care for the right patient at the right time is the biggest part of our mission. We serve patients by transforming the promise of science and biotechnology into clinical treatment that improves their quality of life.
